It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
At Sygnature Discovery, we make synthetic chemistry work for you. Our teams combine creativity, precision, and deep technical expertise to design efficient, scalable routes for even the most challenging molecules, transforming complexity into practical solutions that accelerate your discovery program.
Synthetic excellence delivered at the point of need. Moving fast to troubleshoot and overcome challenges ensures novel compounds delivered for screening without delay.
Across diverse chemical space, we deliver high-quality outcomes through speed, problem-solving, and scalable solutions that keep your program moving forward.
Our purpose-built laboratories house state-of-the-art technologies that enable safe, efficient, and high-quality synthesis. Electronic lab notebooks, in-house LCMS/UPLC systems, high-field NMR spectrometers, and automated purification platforms ensure robust execution and fast analytical turnaround.
Our digital ecosystem strengthens decision-making and reproducibility. Proprietary tools provide continuous performance insights. Access to Reaxys and internal reaction libraries supports rapid troubleshooting and smart route design. Together, these capabilities give our teams precision, confidence, and scientific agility.
Technologies and Modern Methodologies That Accelerate Discovery
We don’t just follow the latest chemistry trends- we implement them. Our teams actively adopt high-impact methodologies from the literature to shorten timelines and expand chemical diversity. We apply advanced approaches to C-C and C –X bond formation and leverage modern techniques such as electrochemistry, photoredox catalysis, flow chemistry, and skeletal editing. These innovations expand chemical space, enhance efficacy, and unlock new synthetic possibilities, all embedded into our daily workflows for smarter design and faster delivery.
High-Throughput Experimentation (HTE) That Solves Challenges Fast
Our dedicated High-Throughput Experimentation (HTE) team accelerates problem-solving for difficult reactions. Using 96-well plate screening and ChemBeads® technology, we evaluate palladium – and copper catalyzed couplings, SNAr, and amide reactions with minimal substrate. Semi automated setup, glovebox operation, and a dedicated Waters iClass UPLC deliver rapid around. Our HTE platform provides practical, data driven solutions that keep projects on track.
Integrated Chemistry That Scales with You
Synthetic chemistry at Sygnature connects seamlessly with platforms like High Throughput Chemistry (HTC), Fragment Libraries, and CHARMED for degrader synthesis. With in-house capabilities for kilogram-scale production (Process Chemistry) and robust technology transfer processes, we deliver reliable routes for non-GLP batches and clinical readiness.
Key Strengths
Solutions, Not Setbacks
We anticipate challenges and propose answers before problems escalate.
Innovation Meets Experience
Drawing on deep experience across diverse chemotypes, from macrocycles to PROTACs, we apply advanced methods and creative problem-solving to deliver differentiated solutions in even the most competitive IP environments.
Speed and Reliability Through Collaboration
Guided by experienced project leaders, our interdisciplinary teams work transparently to meet deadlines and deliver robust outcomes.
Modern Tools, Smarter Workflows
High-throughput experimentation, automated purification, and large-scale reactors ensure precision and reproducibility from milligram to kilo gram scale.
Collaboration is at the heart of how we work. Every project benefits from synthetic know-how, supported by experienced leaders who ensure continuity, clear communication, and alignment with your goals.
Problem solving is part of our culture and identity. We strive to find the correct reaction, first time, every time. Department-wide “Go-to Boxes” capture optimized conditions for key transformations – such as Buchwald, Suzuki, and Mitsunobu – so proven solutions can be reused and refined across programs.
We turn complexity into clarity combining creativity, experience, and modern automation to design efficient, scalable routes for even the most challenging molecules. With transparent communication and rapid problem solving, we deliver high-quality synthesis that accelerates your discovery reliably, efficiently, and with full scientific accountability.
As the demand for greener, more sustainable drug discovery grows, minimising the use of environmentally…
Posters
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Automated high-throughput chemistry delivering rapid, high-quality compound libraries enabling efficient SAR exploration and faster progression from concept to candidate.
Scalable, transfer-ready process chemistry embedded early combining strategic route design and advanced technologies to reduce risk and accelerate progress.
Targeted Protein Degradation (TPD) is an innovative drug discovery approach focused on previously considered ‘undruggable’ proteins. TPD leverages the cell’s ubiquitin-proteasome system to tag these ‘undruggable’ proteins for degradation.
From high -quality starting points to optimized leads, we unite fragment screening, structural biology, computational chemistry and medicinal chemistry to keep your program moving forward .
Clinically focused medicinal chemistry combining design excellence, AI-driven insight, and collaborative expertise to deliver molecules aligned with your goals.
